Geron (GERN) shares +7.8% to $2.59 after Stifel Nicolas initiates the biotech company with a "buy" rating and gives it a price target of $4. The rating adds to the positive buzz surrounding Geron - a Seeking Alpha article earlier this month said the firm's drugs "have the potential to change the way cancer is treated."
Sent to 6,151 people who get email alerts on GERN.
Get email alerts on GERN »
Want to be faster and smarter on all your stocks?
Upgrade all your basic real-time alerts to PRO Alerts, for $30.